Leanne Gasink joined Nabriva Therapeutics in November 2015. She has a bachelor of science from the Pennsylvania State University and a medical degree and masters of science in clinical epidemiology from the University of Pennsylvania. She completed her Internal Medicine and Infectious Diseases training at the University of Pennsylvania. Prior to joining the biopharmaceutical industry, Leanne was the Associate Hospital Epidemiologist and Co-Director of the Antimicrobial Stewardship Program at the Hospital of the University of Pennsylvania. Since 2009, she has focused on the development of treatments for infections due to multi-drug resistant bacteria. She previously held positions at AstraZeneca, where she played a leadership role in the late stage development and subsequent approval of Ceftazadime-avibactam.